EU post-market surveillance - why it's not enough
This article was originally published in Clinica
Executive Summary
Post-market surveillance is a misleading term. It apparently applies only to products after they have been put on the market. Yet manufacturers who ignore pre-clinical and design factors in the post-market assessment of product safety are at risk of product failures and liability problems in the current environment of regulatory change. Amanda Maxwell reports